Results 41 to 50 of about 2,230 (120)
JHLT OpenBackground: Cystic fibrosis (CF) is an autosomal recessive condition leading to progressive lung disease and often necessitating lung transplantation. Historically, CF has been one of the leading indications for lung transplants in the United States. The
Tahuanty A. Pena, MD, MS +3 more
doaj +1 more source
Frontiers in PediatricsBackgroundCystic fibrosis-related diabetes (CFRD) is a common comorbidity in cystic fibrosis (CF), particularly in the pediatric population. As cystic fibrosis transmembrane conductance regulator modulators (CFTRm) become widely used, there is growing ...
Anna Pietrzykowska +6 more
doaj +1 more source
Antibiotics, 2021 The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a ...
Marika Comegna +8 more
doaj +1 more source
Pediatric Pulmonology, Volume 61, Issue 3, March 2026.ABSTRACT Background The metabolic impact of poor diet quality in cystic fibrosis (CF), coupled with a rise in obesity and modulator‐induced weight gain, is a growing concern. Our study aimed to understand knowledge and perspectives regarding dietary changes on modulators, and how measured nutrient intake changes with different dietary patterns in ...
Julianna Bailey +5 more
wiley +1 more source
mBioThe intestinal microbiome influences growth and disease progression in children with cystic fibrosis (CF). Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA), the newest pharmaceutical modulator for CF, restores the function of the pathogenic mutated CF ...
Seth A. Reasoner +10 more
doaj +1 more source
Respiratory Medicine Case Reports, 2022 Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) is a triple combination drug therapy approved for individuals with cystic fibrosis (CF) who possess at least one copy of the F508del cystic fibrosis transmembrane conductance regulator (CFTR) variant.
Elena Stekolchik +2 more
doaj +1 more source
Disparities in Access to Cystic Fibrosis Therapy Across Countries
Pediatric Pulmonology, Volume 61, Issue 3, March 2026.ABSTRACT Cystic fibrosis has been transformed by the development of CFTR modulator therapies, with substantial improvements in survival and quality of life. However, access to these therapies remains profoundly unequal worldwide. The greatest benefits have been realized in high‐income countries, while people with cystic fibrosis in low‐ and middle ...
Bulent Karadag
wiley +1 more source
Open Systems Pharmacology Community Conference (OSP‐CC) Proceedings 2025
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.ABSTRACT Developed at Bayer Technology Services, PK‐Sim and MoBi transitioned into the Open Systems Pharmacology (OSP) Suite, released as free open‐source software in 2017. An active community with stakeholders from academia, industries, and regulators contributes to the continuous improvement of open‐source model‐informed drug development (MIDD). This
Henrik Cordes +35 more
wiley +1 more source
ERJ Open ResearchBackground People living with cystic fibrosis in Denmark had early, universal access to triple modulator treatment with elexacaftor/tezacaftor/ivacaftor.
Christian Leo-Hansen +19 more
doaj +1 more source
Sodium Glucose‐Like Co‐Transporter 2 Inhibitor (SGLT2i) Use in Adults With Cystic Fibrosis
Respirology Case Reports, Volume 14, Issue 3, March 2026.Use of sodium glucose‐like co‐transporter 2 inhibitors in people with cystic fibrosis may be considered for glycaemic, renal and cardiac benefits. We described safe, tolerable and effective use in three adults with CF. ABSTRACT Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) also called flozins or gliflozins have been demonstrated to have multi ...
Ellie Johnson +3 more
wiley +1 more source